Contract Research & Services
Contract Services

Contract Services News

View news from other Pharmaceutical sectors:
1-15 of 2371 results
Mylan to buy global marketing rights of Mapi’s Glatiramer acetate product
Mylan has agreed to acquire global marketing rights of Israel-based Mapi Pharma’s GA Depot, a long-acting once-monthly Glatiramer acetate product.
Contract Research & Services > Contract Services > News
Ionis licenses to Akcea global rights to inotersen in $1.7bn deal
By PBR Staff Writer
Ionis Pharmaceuticals has licensed to Akcea Therapeutics worldwide rights to inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx, in a transaction potentially worth about $1.7bn.
Contract Research & Services > Contract Services > News
Valeant, Kaken sign license deal to develop new chemical entity for psoriasis
Valeant Pharmaceuticals International's subsidiary and Kaken Pharmaceutical have entered into a license agreement to develop and commercialize products featuring KP-470, an investigational compound for the topical treatment of psoriasis.
Contract Research & Services > Contract Services > News
Arvinas, Genentech expand license agreement for Protac
Arvinas has expanded its ongoing license agreement with Genentech for the development of new therapeutics using its novel PROTAC technology.
Contract Research & Services > Contract Services > News
Xenetic signs sublicense deal related to PolyXen technology with Baxalta
Xenetic Biosciences has entered into a Right to Sublicense Agreement with Baxalta, Baxalta, and Baxalta (collectively, with their affiliates, “Baxalta”), wholly-owned subsidiaries of Shire.
Contract Research & Services > Contract Services > News
Avadel secures exclusive rights to nocturia candidate Noctiva in US and Canada
Avadel Pharmaceuticals has entered into a license agreement with Serenity Pharmaceuticals, which grants Avadel the sole right to commercialize and further develop Noctiva in the US and Canada.
Contract Research & Services > Contract Services > News
Ligand to receive $2m from WuXi for licensing clinical-stage anti-PD-1 antibody
Ligand Pharmaceuticals will get a payment of $2m from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and other selected territories.
Contract Research & Services > Contract Services > News
Oxford BioMedica secures commercial supply licence from UK MHRA
Oxford BioMedica has been granted a Manufacturer/Importer License (MIA) from the UK Medicines and Healthcare products Regulatory Agency (MHRA), to manufacture and distribute lentiviral vector material for commercial supply.
Contract Research & Services > Contract Services > News
Sunovion to sell asthma and allergy products to Covis Pharma
Sunovion Pharmaceuticals has agreed to sell the US market rights to its ciclesonide products Alvesco (ciclesonide) Inhalation Aerosol, Omnaris (ciclesonide) Nasal Spray, and Zetonna (ciclesonide) Nasal Aerosol to Covis Pharma.
Contract Research & Services > Contract Services > News
Emergent BioSolutions to buy Sanofi’s smallpox vaccine business for $125m
By PBR Staff Writer
Emergent BioSolutions has agreed to acquire Sanofi’s smallpox vaccine business for around $125m.
Contract Research & Services > Contract Services > News
Shield, Ewopharma partner to commercialize Feraccru in Switzerland
Shield Therapeutics and Ewopharma have entered into an exclusive sale, supply, distribution and marketing agreement for Feraccru in Switzerland.
Contract Research & Services > Contract Services > News
Alexion signs funding deal with NICE and NHS England for Strensiq
Alexion Pharmaceuticals has signed a national funding agreement with the National Institute for Health and Care Excellence (NICE) and the National Health Service (NHS) England based on a Managed Access Agreement (MAA), which provides access to Strensiq (asfotase alfa) for patients in England with pediatric-onset hypophosphatasia (HPP), regardless of their current age.
Contract Research & Services > Contract Services > News
eFFECTOR partners with Pfizer, Merck to evaluate combination of two immuno-oncology agents
eFFECTOR Therapeutics has entered into a clinical collaboration and supply agreement with Pfizer and Merck to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC).
Contract Research & Services > Contract Services > News
Immune Pharmaceuticals signs deal to regain global rights for Ceplene
Immune Pharmaceuticals has signed an agreement with Mylan company Meda to repurchase assets relating to Ceplene, including the right to commercialize it in Europe and to register and commercialize in several other countries.
Contract Research & Services > Contract Services > News
Pfizer to commercialize Basilea's Cresemba drug in Europe
Basilea Pharmaceutica International has signed a license agreement with Pfizer for its marketed antifungal Cresemba (isavuconazole) to treat life-threatening invasive mold infections.
Contract Research & Services > Contract Services > News
1-15 of 2371 results